SNSS - Sunesis Pharmaceuticals, Inc.
| Previous Close | 1.25 |
| Open | 1.24 |
| Bid | 1.12 x 1200 |
| Ask | 1.59 x 1400 |
| Day's Range | 1.18 - 1.39 |
| 52 Week Range | 1.12 - 7.69 |
| Volume | 185,363 |
| Avg. Volume | 112,517 |
| Market Cap | 46.028M |
| Beta (3Y Monthly) | 2.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- GlobeNewswire•3 days ago
Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of SNSS earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Sunesis Pharmaceuticals Inc Earnings Call
- Associated Press•12 days ago
Sunesis: 3Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 18 cents. In the final minutes of trading on Monday, the company's shares hit $1.32. A year ago, they were ...
- GlobeNewswire•13 days ago
Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported.
- GlobeNewswire•17 days ago
Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two poster presentations and an oral presentation at the 60th.
- GlobeNewswire•20 days ago
Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Monday, November 5th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
- GlobeNewswire•2 months ago
Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 4:00 P.M. Eastern Time at the Intercontinental Barclay Hotel in New York City. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia.
- Simply Wall St.•2 months ago
Should You Worry About The Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS) Shareholder Register?
A look at the shareholders of Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of SNSS earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 Sunesis Pharmaceuticals Inc Earnings Call
- GlobeNewswire•3 months ago
Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Wells Fargo Securities 2018 Healthcare Conference on Thursday, September 6, 2018 at 10:20 A.M. Eastern Time at the Westin Copley Place in Boston, MA. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia.
- Associated Press•3 months ago
Sunesis: 2Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 20 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $2.45. A year ago, they were trading at ...
- Zacks•5 months ago
5 Biotech Stocks Under $10 Worthy of Investors' Attention
Small biotech stocks are good bets with lower market cap as well as share price.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of SNSS earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 Sunesis Pharmaceuticals Inc Earnings Call
- Associated Press•6 months ago
Sunesis: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 21 cents per share. The biopharmaceutical company posted revenue of $237,000 in the period. In the final minutes of trading on Tuesday, ...
- Zacks•7 months ago
Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock?
Investors in Sunesis Pharmaceuticals (SNSS) need to pay close attention to the stock based on moves in the options market lately.
- Thomson Reuters StreetEvents•8 months ago
Edited Transcript of SNSS earnings conference call or presentation 8-Mar-18 9:30pm GMT
Q4 2017 Sunesis Pharmaceuticals Inc Earnings Call
